Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

One of these mRNA pioneers has the products and pipeline to drive growth.

  • Moderna and BioNTech transitioned beyond coronavirus vaccines in 2026
  • BioNTech's future depends on CEO and CMO leadership transition by Feb 1
  • Moderna has commercialized flu vaccine and advancing intismeran in oncology

SK hynix Weighs Kioxia Bond Conversion

SK hynix is considering a plan to convert the convertible bonds it secured through its investment in the Japanese NAND flash manufacturer Kioxia into shares.According to the industry on Nov.

  • SK hynix considering converting Kioxia convertible bonds to shares.
  • Investment of 395 billion yen ($2.92 billion) in Kioxia via Bain Capital.
  • Bond conversion would grant SK hynix majority voting control in SPC2.

More from Friday 20 November →